Mechanical circulatory support therapy in advanced heart failure

Mechanical Circulatory Support Therapy in Advanced Heart Failure

Volumn , Issue , 2007, Pages 1-404

  Deng, Mario C ^a   Naka, Yoshifumi ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84967373619     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/P481     Document Type: Book

References (365)

1. Aaronson KD, Mancini DM. Mortality remains high for outpatient transplant candidates with prolonged (>6 months) waiting list time. J Am Coll Cardiol 1999;33:1189-95.
2. Aaronson KD, Patel H, Pagani FD. Patient selection for left ventricular assist device therapy. Ann Thorac Surg 2003;75(6 Suppl):S29-35.
3. Aaronson KD, Schwartz JS, Chen TM, et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 1997;95:2660-7.
4. Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000;342:1301-8.
5. Aleksic I, Baryalei MM, Schorn B, et al. Resection for CMV ileitis in a patient supported by a left-ventricular assist device. Thorac Cardiovasc Surg 1998;46:105-6.
6. Andrus S, Dubois J, Jansen C, et al. Teaching documentation tool: building a successful discharge. Crit Care Nurse 2003;23:39-48.
7. Angermann CE, Costard-Jaeckle A, Deng MC, for the EFICAT Investigators. Efficacy and safety of carvedilol in severe heart failure patients accepted for heart transplantation (abstr). J Am Coll Cardiol 2001;37(Suppl A):179A.
8. Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997;349:1050-3.
9. Ankersmit HJ, Tugulea S, Spanier T, et al. Activation-induced T-cell death and immune dysfunction after implantation of left-ventricular assist device. Lancet 1999;354:550-5.
10. Ankersmit HJ, Wieselthaler G, Moser B, et al. Transitory immunologic response after implantation of the DeBakey VAD continuous-axial-flow pump. J Thorac Cardiovasc Surg 2002;123:557-61.
11. Annane D, Bellissant E, Bollaert PE, et al. Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis. BMJ 2004; 329:480.
12. Aretz HT, Billingham ME, Edwards WD, et al. Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol 1987;1:3-14.
13. Argenziano M, Chen JM, Choudhri AF, et al. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg 1998;116:973-80.
14. Aronson S, Blumenthal R. Perioperative renal dysfunction and cardiovascular anesthesia: concerns and controversies. J Cardiothorac Vasc Anesth 1998;12:567-86.
15. Arrecubieta C, Asai T, Bayern M, et al. The role of Staphylococcus aureus adhesins in the pathogenesis of ventricular assist device-related infections. J Infect Dis 2006;193(8):1109-19.
16. Asai T, Baron HM, von Bayern MP, et al. A mouse aortic patch model for mechanical circulatory support. J Heart Lung Transplant 2005;24:1129-32.
17. Asai T, Lee M, Arrecubieta C, et al. Cellular coating of the left ventricular assist device textured polyurethane membrane reduces adherence of Staphylococcus aureus. Thorac Cardiovasc Surg (in press).
18. Athanasuleas CL, Buckberg GD, Stanley AW, et al.; RESTORE group. Surgical ventricular restoration in the treatment of congestive heart failure due to postinfarction ventricular dilation. J Am Coll Cardiol 2004;44:1439-45.
19. Athanasuleas CL, Stanley AW Jr, Buckberg GD, et al. Surgical anterior ventricular endocardial restoration (SAVER) in the dilated remodeled ventricle after anterior myocardial infarction. J Am Coll Cardiol 2001;37:1199-209.
20. AVID Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med 1997;337:1576-83.
21. Barbone A, Pini D, Grossi P, et al. Aspergillus left ventricular assist device endocarditis. Ital Heart J 2004;5:876-80.
22. Barbone A, Rao V, Oz MC, Naka Y. LVAD support in patients with bioprosthetic valves. Ann Thorac Surg 2002;74:232-4.
23. Bardy GH, Lee KL, Mark DB, et al.; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverterdefibrillator for congestive heart failure. N Engl J Med 2005;352:225-37.
24. Basso K, Margolin A, Stolovitzky G, et al. Reverse engineering of regulatory networks in human B cells. Nat Genet 2005;37(4):382-90.
25. Baudouin SV, Evans TW. Nutritional support in critical care. Clin Chest Med 2003;24(4):633-44.
26. Bennett M, Horton S, et al. Pump-induced haemolysis: a comparison of short-term ventricular assist devices. Perfusion 2004;19(2):107-11.
27. Bernard GR, Vincent JL, Laterre PF, et al.; Recombinant Human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
28. Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med 1997;337:1569-75.
29. Birks EJ, Hall JL, Barton PJ, et al. Gene profiling changes in cytoskeletal proteins during clinical recovery after left ventricular-assist device support. Circulation 2005;112(9 Suppl):I57-64.
30. Bolling SF, Pagani FD, Deeb GM, Bach DS. Intermediate-term outcome of mitral reconstruction in cardiomyopathy. Thorac Cardiovasc Surg 1998;115:381-6.
31. Bonaros N, Mueller MR, Salat A, et al. Extensive coagulation monitoring in patients after implantation of the MicroMed DeBakey continuous flow axial pump. ASAIO J 2004;50:424-31.
32. Bonkohara Y, Minami K, Arusoglu L, et al. A fatal mechanical disorder of the TCI Heart Mate left ventricular assist system. J Thorac Cardiovasc Surg 1999;118:769-70.
33. Bramstedt KA, Nash PJ. When death is the outcome of informed refusal: dilemma of rejecting ventricular assist device therapy. J Heart Lung Transplant 2005;24:229-30.
34. Brandt M, Koch MT, Steinhoff G, et al. Do long-term results justify bridging to heart transplantation in patients with multi-organ dysfunction? Thorac Cardiovasc Surg 1996;44:277-81.
35. Braunwald E (ed.). Heart Disease. A Textbook of Cardiovascular Medicine (4th ed.). Saunders, Philadelphia, 1992.
36. Bristow MR, Feldman AM, Saxon LA. Heart failure management using implantable devices for ventricular resynchronization: Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure (COMPANION) trial. COMPANION Steering Committee and COMPANION Clinical Investigators. J Card Fail 2000;6:276-85.
37. Bristow MR, Saxon LA, Boehmer J, et al. Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140-50.
38. Bryant AS, Holman WL, Nanda NC, et al. Native aortic valve insufficiency in patients with left ventricular assist devices. Ann Thorac Surg 2006;81:e6-8.
39. Bunzel B, Laederach-Hofmann K, Wieselthaler GM, et al. Posttraumatic stress disorder after implantation of a mechanical assist device followed by heart transplantation: evaluation of patients and partners. Transplant Proc 2005;37:1365-8.
40. Butler J, Forman DE, Abraham WT, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004;147(2):331-8.
41. Butler J, Howser R, Portner PM, Pierson RN III. Body mass index and outcomes after left ventricular assist device placement. Ann Thorac Surg 2005; 79(1): 66-73.
42. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999;341:1882-90.
43. Byers J, Sladen RN. Renal function and dysfunction. Curr Opin Anaesthesiol 2001;14:699-706.
44. Cadeiras M, Von Bayern MP, Pal A, et al. Destination therapy: an alternative for end-stage heart failure patients not eligible for heart transplantation. Curr Opin Organ Transplant 2005;10:369-75.
45. Califf RM, Adams KF, Mckenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997;134:44-54.
46. Cappuccio FP. Commentary: epidemiological transition, migration, and cardiovascular disease. Int J Epidemiol 2004;33:387-8.
47. Cazeau S, Leclercq C, Lavergne T, et al.; Multisite Stimulation in Cardiomyopathies (MUSTIC) Study Investigators. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001;344:873-80.
48. Cengiz P, Seidel K, Rycus PT, et al. Central nervous system complications during pediatric extracorporeal life support: incidence and risk factors. Crit Care Med 2005;33:2817-24.
49. Cesario DA, Dec GW. Implantable cardioverter-defibrillator therapy in clinical practice. J Am Coll Cardiol 2006;47:1507-17.
50. Chen L, McCulloch AD, May-Newman K. Nonhomogeneous deformation in the anterior leaflet of the mitral valve. Ann Biomed Eng 2004;32:1599-606.
51. Chinn R, Dembitsky W, Eaton L, et al.; Multicenter experience: prevention and management of left ventricular assist device infections. ASAIO J 2005;51: 461-70.
52. Christensen E. Prognostic models including the Child-Pugh, MELD and Mayo risk scores - where are we and where should we go? J Hepatol 2004;41: 344-50.
53. CIBIS-II Study Group. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
54. Cleland JG, Coletta AP, Lammiman M, et al. Clinical trials update from the European Society of Cardiology meeting 2005: CARE-HF extension study, ESSENTIAL, CIBIS-III, S-ICD, ISSUE-2, STRIDE-2, SOFA, IMAGINE, PREAMI, SIRIUS-II and ACTIVE. Eur J Heart Fail 2005;7:1070-5.
55. Cleland JG, Freemantle N, Coletta AP, Clark AL. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail 2006;8:105-10.
56. Cohn JN, Goldstein SO, Greenberg BH, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med 1998;339:1810-6.
57. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure. New Engl J Med 2001;345:1667-75.
58. Consales G, De Gaudio AR. Sepsis associated encephalopathy. Minerva Anestesiol 2005;71:39-52.
59. Cooper DK, Keogh AM. The potential role of xenotransplantation in treating endstage cardiac disease: a summary of the report of the Xenotransplantation Advisory Committee of the International Society for Heart and Lung Transplantation. Curr Opin Cardiol 2001;16:105-9.
60. Cooper LT Jr. Giant cell myocarditis: diagnosis and treatment. Herz 2000;25: 291-8.
61. Cooper LT Jr., Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis - natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. N Engl J Med 1997;336:1860-6.
62. Copeland JG, Smith RG, Arabia FA, et al.; Cardio West Total Artificial Heart Investigators. Cardiac replacement with a total artificial heart as a bridge to transplantation. N Engl J Med 2004;351:859-67.
63. Copeland JG 3rd, Smith RG, Arabia FA, et al. Comparison of the Cardio West total artificial heart, the Novacor left ventricular assist system and the Thoratec ventricular assist system in bridge to transplantation. Ann Thorac Surg 2001;71(3 Suppl):S92-7.
64. Cowie MR, Wood DA, Coats AJ, et al. Survival of patients with a new diagnosis of heart failure: a population based study. Heart 2000;83:505-10.
65. Crespo Leiro MG, Paniagua Martin MJ. Management of advanced or refractory heart failure. Rev Esp Cardiol 2004;57:869-83.
66. Cuffe MS, Califf RM, Adams KF Jr., et al.; Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIMECHF) Investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002;287: 1541-7.
67. D'Aiuto F, Casas JP, Shah T, et al. C-reactive protein (+1444C>T) polymorphism influences CRP response following a moderate inflammatory stimulus. Atherosclerosis 2005;179:413-7.
68. Dandel M, Weng Y, Siniawski H, et al. Long-term results in patients with idiopathic dilated cardiomyopathy after weaning from left ventricular assist devices. Circulation 2005;112(Suppl 9):I37-45.
69. Dang NC, Topkara VK, Kim BT, et al. Nutritional status in patients on left ventricular assist device support. J Thorac Cardiovasc Surg 2005; 130:e3-4.
70. Dang NC, Topkara VK, Mercando M, et al. Right heart failure after left ventricular assist device implantation in patients with chronic congestive heart failure. J Heart Lung Transplant 2006;25:1-6.
71. DeBakey ME. Development of mechanical heart devices. Ann Thorac Surg 2005;79:S2228-31.
72. Dellinger RP, Carlet JM, Masur H, et al.; Surviving Sepsis Campaign Management Guidelines Committee. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32: 858-73.
73. DembitskyWP, Tector AJ, Park S, et al. Left ventricular assist device performance with long-term circulatory support: lessons from the REMATCH trial. Ann Thorac Surg 2004;78:2123-9.
74. Deng MC. Cardiac transplantation. Heart 2002;87:177-84.
75. Deng MC. The challenges of generating evidence to guide mechanical circulatory support-based management of advanced heart failure (editorial). Eur Heart J 2005;26:953-5.
76. Deng MC, De Meester JMJ, Smits JMA, on behalf of COCPIT Study Group. The effect of receiving a heart transplant: analysis of a national cohort entered onto a waiting list, stratified by heart failure severity. Br Med J 2000;321:540-5.
77. Deng MC, Edwards LB, Hertz MI, et al. Mechanical Circulatory Support Device Database of the International Society for Heart and Lung Transplantation: second annual report - 2004. J Heart Lung Transplant 2004;23: 1027-34.
78. Deng MC, Edwards LB, Taylor DO, et al. Mechanical Circulatory Support Device Database of the International Society for Heart and Lung Transplantation: third annual report - 2005. J Heart Lung Transplant 2005a;24:1182-7.
79. Deng MC, Erren M, Tamminga N, et al. Left ventricular assist system support is associated with persistent inflammation and temporary immunosuppression. Thorac Cardiovasc Surg 1999a;47(Suppl):326-31.
80. Deng MC, Loebe M, El-Banayosi A, et al. Mechanical circulatory support for advanced heart failure: effect of patient selection on outcome. Circulation 2001a;103:231-7.
81. Deng MC, Mehra MC, Eisen HJ, et al. Cardiac allograft monitoring using a novel clinical algorithm based on peripheral leukocyte gene expression profiling (abstr). Circulation 2003a;108:IV-398.
82. Deng MC, Naka Y. Circulatory support in advanced heart failure. Cardiol Rev 2002;19:28-35.
83. Deng MC, Ranjit J, Baron H, et al. Transplantation immunology. In: Compston J, Shane E (eds.). Bone Disease of Organ Transplantation. Elsevier Academic Press, San Diego, 2005b, pp. 3-29.
84. Deng MC, Smits JMA, De Meester J, et al. Heart transplantation is indicated only in the most severely ill patient: perspectives from the German heart transplant experience. Curr Opin Cardiol 2001b;16:97-104.
85. Deng MC, Smits JMA, Packer M. Selecting patients for heart transplantation: which patients are too well for transplant? Curr Opin Cardiol 2002;17: 137-44.
86. Deng MC, Smits JMA, Young JB. Proposition: the benefit of cardiac transplantation in stable outpatients with heart failure should be tested in a randomized trial. J Heart Lung Transplant 2003b;22:113-7.
87. Deng MC, Tjan TD, Asfour B, et al. Combining nonpharmacologic therapies for advanced heart failure: the Münster experience with the assist devicedefibrillator combination. Am J Cardiol 1999b;83:158D-60D.
88. Deng MC, Wilhelm M, WeyandM, et al. Long-term left ventricular assist device support: a novel pump rate challenge exercise protocol to monitor native left ventricular function. J Heart Lung Transplant 1997;16:629-35.
89. Deng MC, Wilhelm MJ, Scheld HH. Effects of exercise during long-term support with a left ventricular assist device (letter). Circulation 1998;97: 1212-3.
90. Deng MC, Young JB, Stevenson LW, et al.; Board of Directors of the International Society for Heart and Lung Transplantation. Destination mechanical circulatory support: proposal for clinical standards. J Heart Lung Transplant 2003c;22:365-9.
91. DeNofrio D, Rho R, Morales FJ, et al. Detection of anti-HLA antibody by flow cytometry in patients with a left ventricular assist device is associated with early rejection following heart transplantation. Transplantation 2000;69: 814-8.
92. Dew MA, Kormos RL, DiMartini AF. Prevalence and risk of depression and anxiety-related disorders during the first three years after heart transplantation. Psychosomatics 2001a;42:300-13.
93. Dew MA, Kormos RL, Winowich S, et al. Quality of life outcomes in left ventricular assist system inpatients and outpatients. ASAIO J 1999;45: 218-25.
94. Dew MA, Kormos RL, Winowich S, et al. Quality of life outcomes after heart transplantation in individuals bridged to transplant with ventricular assist devices. J Heart Lung Transplant 2001b;20:1199-212.
95. Di Carli MF, Asgarzadie F, Schelbert HR, et al. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy. Circulation 1995;92: 3436-44.
96. Digiorgi PL, Reel MS, Thornton B, et al. Heart transplant and left ventricular assist device costs. J Heart Lung Transplant 2005;24:200-4.
97. DiNardo MM, Korytkowski MT, Siminerio LS. The importance of normoglycemia in critically ill patients. Crit Care Nurs Q 2004;27:126-34.
98. Doval HC, Nul DR, Grancelli HO, et al. Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994;344:493-8.
99. Dowling RD, Gray LA Jr, Etoch SW, et al. Initial experience with the Abio- Cor implantable replacement heart system. J Thorac Cardiovasc Surg 2004; 127:131-41.
100. Dreyfus G, Duboc D, Blasco A, et al. Coronary surgery can be an alternative to heart transplantation in selected patients with end-stage ischemic heart disease. Eur J Cardiothorac Surg 1993;7:482-8.
101. Edwards NM, Prager KM. Nothing is fair or good alone. J Thorac Cardiovasc Surg 2003;125:23-4.
102. El Oakley RM, Ooi OC, Bongso A, Yacoub MH. Myocyte transplantation for myocardial repair: a few good cells can mend a broken heart. Ann Thorac Surg 2001;71:1724-33.
103. El-Amir NG, Gardocki M, Levin HR, et al. Gastrointestinal consequences of left ventricular assist device placement. ASAIO J 1996;42:150-3.
104. El-Banayosy A, Arusoglu L, Kizner L, et al. Novacor left ventricular assist system versus Heart Mate vented electric left ventricular assist system as a long-term mechanical circulatory support device in bridging patients: a prospective study. J Thorac Cardiovasc Surg 2000;119:581-7.
105. El-Banayosy A, Arusoglu L, Kizner L, et al. Preliminary experience with the Lion Heart left ventricular assist device in patients with end-stage heart failure. Ann Thorac Surg 2003;75:1469-75.
106. El-Banayosy A, Fey O, Sarnowski P, et al. Midterm follow-up of patients discharged from hospital under left ventricular assistance. J Heart Lung Transplant 2001;20:53-8.
107. Elefteriades JA, Tolis G, Levi E, et al. Coronary artery bypass grafting in severe left ventricular dysfunction: excellent survival and improved EF and functional state. J Am Coll Cardiol 1993;22:1411-7.
108. Ely EW, Laterre PF, Angus DC, et al.; PROWESS Investigators. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003;31:12-9.
109. Etzion S, Battler A, Barbash IM, et al. Influence of embryonic cardiomyocyte transplantation on the progression of heart failure in a rat model of extensive myocardial infarction. J Mol Cell Cardiol 2001;33:1321-30.
110. Federal Register. April 2, 1998;63:16296.
111. Feldman AM, Bristow MR, Parmley WW, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. N Engl J Med 1993;329:149-55.
112. Felker GM, Rogers JG. Same bridge, new destinations: rethinking paradigms for mechanical cardiac support in heart failure. J Am Coll Cardiol 2006;47: 930-2.
113. Ferns J, Dowling R, Bhat G. Evaluation of a patient with left ventricular assist device dysfunction. ASAIO J 2001;47:696-8.
114. Fonarow GC, Stevenson LW, Walden JA, et al. Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. J Am Coll Cardiol 1997;30:725-32.
115. Frazier OH. Mechanical circulatory support: new advances, new pumps, new ideas. Semin Thorac Cardiovasc Surg 2002;14:178-86.
116. Frazier OH, Delgado RM. Mechanical circulatory support for advanced heart failure: where does it stand in 2003? Circulation 2003;108:3064-8.
117. Frazier OH, Delgado RM 3rd, Scroggins N, et al. Mechanical bridging to improvement in severe acute "nonischemic, nonmyocarditis" heart failure. Congest Heart Fail 2004a;10:109-13.
118. Frazier OH, Dowling RD, Gray LA Jr, et al. The total artificial heart: where we stand. Cardiology 2004b;101:117-21.
119. Frazier OH, Kirklin JK (eds.). Mechanical Circulatory Support (ISHLT Monograph Series, Vol. 1). Elsevier, Philadelphia, 2006.
120. Frazier OH, Rose EA, Oz MC, et al.; Heart Mate LVAS Investigators. Multicenter clinical evaluation of the Heart Mate vented electric left ventricular assist system in patients awaiting heart transplantation. J Thorac Cardiovasc Surg 2001;122:1186-95.
121. Frigerio M, Gronda EG, Mangiavacchi M, et al. Restrictive criteria for heart transplantation candidacy maximize survival of patients with advanced heart failure. J Heart Lung Transplant 1997;16:160-8.
122. Fukamachi K, McCarthy PM, Smedira NG, et al. Preoperative risk factors for right ventricular failure after implantable left ventricular assist device insertion. Ann Thorac Surg 1999;68:2181-4.
123. Gelijns AC, Richards AF, Williams DL, et al. Evolving costs of longterm left ventricular assist device implantation. Ann Thorac Surg 1997;64: 1312-9.
124. Gibbons RD, Meltzer D, Duan N, and other members of the Institute of Medicine Committee on Organ Procurement and Transplantation. Waiting for organ transplantation. Science 2000;287:237-8.
125. Golding LAR, El-Banayosy A, Kormos RL, et al. Emerging left ventricular assist devices. In: Frazier OH, Kirklin JK (eds.). Mechanical Circulatory Support (ISHLT Monograph Series, Vol. 1). Elsevier, Philadelphia, 2006, pp. 205-18.
126. Goldstein D, Oz MC (eds.). Cardiac Assist Devices. Futura Publishing, New York, 2000.
127. Goldstein DJ, Moazami N, Seldomridge JA, et al. Circulatory resuscitation with left ventricular assist device support reduces interleukins 6 and 8 levels. Ann Thorac Surg 1997;63:971-4.
128. Goldstein DJ, Zucker M, Arroyo L, et al. Safety and feasibility trial of the Micro Med DeBakey ventricular assist device as a bridge to transplantation. J Am Coll Cardiol 2005;45:962-3.
129. Gordon D, Shore E. University of Pennsylvania VAD/Heart Transplantation Psychosocial Evaluation Tool. 2000.
130. Gordon RJ, Quagliarello B, Lowy FD. Ventricular assist device-related infections. Lancet Infect Dis 2006;6:426-37.
131. Gordon SM, Schmitt SK, Jacobs M, et al. Nosocomial bloodstream infections in patients with implantable left ventricular assist devices. Ann Thorac Surg 2001;72:725-30.
132. Grady KL, Jalowiec A, White-Williams C. Improvement in quality of life in patients with heart failure who undergo transplantation. J Heart Lung Transplant 1996;15:749-57.
133. Grady KL, Jalowiec A, White-Williams C. Quality of life 6 months after heart transplantation compared with indicators of illness severity before transplantation. Am J Crit Care 1998;7:106-16.
134. Grady KL, Meyer P, Mattea A, et al. Predictors of quality of life at 1 month after implantation of a left ventricular assist device. Am J Crit Care 2002;11: 345-52.
135. Grady KL, Meyer PM, Dressler D, et al. Longitudinal change in quality of life and impact on survival after left ventricular assist device implantation. Ann Thorac Surg 2004;77:1321-7.
136. Grady KL, Meyer PM, Mattea A, et al. Change in quality of life from before to after discharge following left ventricular assist device implantation. J Heart Lung Transplant 2003;22:322-33.
137. Granfeldt H, Koul B, Wiklund L, et al. Risk factor analysis of Swedish left ventricular assist device (LVAD) patients. Ann Thorac Surg 2003;76: 1993-8.
138. Gwechenberger M, Hülsmann M, Berger R, et al. Interleukin-6 and B-type natriuretic peptide are independent predictors for worsening of heart failure in patients with progressive congestive heart failure. J Heart Lung Transplant 2004;23:839-44.
139. Hammel D, Tjan DT, Scheld HH, et al. Successful treatment of a Novacor LVAD malfunction without repeat sternotomy. Thorac Cardiovasc Surg 1998;46: 154-6.
140. Hammer C. Xenotransplantation: perspectives and limits. Blood Purif 2001;19: 322-8.
141. Hampton JR, van Veldhuisen DJ, Kleber FX, et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet 1997;349:971-7.
142. Hasper D, Hummel M, Kleber FX, et al. Systemic inflammation in patients with heart failure. Eur Heart J 1998;19:761-5.
143. Hauptman PJ, Havranek EP. Integrating palliative care into heart failure care. Arch Intern Med 2005;165:374-8.
144. Hausmann H, Topp H, Siniawski H, et al. Decision-making in end-stage coronary artery disease: revascularization or heart transplantation? Ann Thor Surg 1997;64:1296-302.
145. Helman DN, Maybaum SW, Morales DL, et al. Recurrent remodeling after ventricular assistance: is long-term myocardial recovery attainable? Ann Thorac Surg 2000;70:1255-8.
146. Henger A, Kretzler M, Doran P. Gene expression fingerprints in human tubulointerstitial inflammation and fibrosis as prognostic markers of disease progression. Kidney Int 2004;65:904-17.
147. Hermann M, Weyand M, Greshake B, et al. Left ventricular assist device infection is associated with increased mortality but is not a contraindication to transplantation. Circulation 1997;95:814-7.
148. Hernandez AF, Grab J, Gammie JS, et al. A decade of acute outcomes in post cardiac surgery ventricular assist device implantation: data from the Society of Thoracic Surgeons' National Cardiac Database. Circulation (in press).
149. Hetzer R, Muller J, Weng Y, et al. Cardiac recovery in dilated cardiomyopathy by unloading with a left ventricular assist device. Ann Thorac Surg 1999;68: 742-9.
150. Hetzer R, Muller JH, Weng Y, et al. Bridging-to-recovery. Ann Thorac Surg 2001;71(3 Suppl):S109-13.
151. Hetzer R, Muller JH, Weng YG, et al. Midterm follow-up of patients who underwent removal of a left ventricular assist device after cardiac recovery from end-stage dilated cardiomyopathy. J Thorac Cardiovasc Surg 2000;120: 843-55.
152. Hetzer R, Weng Y, Potapov EV, et al. First experiences with a novel magnetically suspended axial flow left ventricular assist device. Eur J Cardiothorac Surg 2004;25:964-70.
153. Hogness JR, VanAntwerp M (eds.). The artificial heart program. In: The Artificial Heart: Prototypes, Policies, and Patients. National Academy Press, Washington, 1991, pp. 14-25.
154. Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004;351:2481-8.
155. Holman WL, Bourge RC, Fan P, et al. Influence of longer term left ventricular assist device support on valvular regurgitation. ASAIO J 1994;40:M454-9.
156. Holman WL, Bourge RC, Murrah CP, et al. Left atrial or ventricular cannulation beyond 30 days for a Thoratec ventricular assist device. ASAIO J 1995;41:M517-22.
157. Holman WL, Davies JE, Rayburn BK, et al. Treatment of end-stage heart disease with outpatient ventricular assist devices. Ann Thorac Surg 2002;73:1489-93.
158. Holman WL, Fix RJ, Foley BA, et al. Management of wound and left ventricular assist device pocket infection. Ann Thorac Surg 1999;68:1080-2.
159. Holman WL, Park SJ, Long JW, et al.; REMATCH Investigators. Infection in permanent circulatory support: experience from the REMATCH trial. J Heart Lung Transplant 2004;23:1359-65.
160. Horton SC, Khodaverdian R, Chatelain P, et al. Left ventricular assist device malfunction: an approach to diagnosis by echocardiography. J Am Coll Cardiol 2005;45:1435-40.
161. Hosenpud JD, Bennett LE, Keck BM, et al. The Registry of the International Society for Heart and Lung Transplantation: sixteenth official report - 1999. J Heart Lung Transplant 1999;18:611-26.
162. Hosenpud JD, Bennett LE, Keck BM, et al. The Registry of the International Society for Heart and Lung Transplantation: eighteenth official report- 2001. J Heart Lung Transplant 2001;20:805-15.
163. Hotz H, Linneweber J, Dohmen PM, et al. Bridge-to-recovery from acute myocarditis in a 12-year-old child. Artif Organs 2004;28:587-9.
164. Houel R, Mazoyer E, Boval B, et al. Platelet activation and aggregation profile in prolonged external ventricular support. J Thorac Cardiovasc Surg 2004;128:197-202.
165. Houel R, Moczar M, Ginat M, Loisance D. Pseudointima in inflow and outflow conduits of a left ventricular assist system: possible role in clinical outcome. ASAIO J 2001;47:275-81.
166. Hunt SA. A fair way of donating hearts for transplantation. BMJ 2000; 321:526.
167. Hunt SA, Abraham WT, Chin MH, et al. American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. Circulation 2005;112: e154-235.
168. Hunt SA, Baker DW, Chin MH, et al.; American College of Cardiology/American Heart Association. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2001;38: 2101-13.
169. Hunt SA, Rider AK, Stinson EB, et al. Does cardiac transplantation prolong life and improve its quality? An updated report. Circulation 1976;54(Suppl III):56-60.
170. Hutcheson KA, Atkins BZ, Hueman MT, et al. Comparison of benefits on myocardial performance of cellular cardiomyoplasty with skeletal myoblasts and fibroblasts. Cell Transplant 2000;9:359-68.
171. Itescu S, John R. Interactions between the recipient immune system and the left ventricular assist device surface: immunological and clinical implications. Ann Thorac Surg 2003;75:S58-65.
172. Jaski BE, Kim JC, Naftel DC, et al.; Cardiac Transplant Research Database Research Group. Cardiac transplant outcome of patients supported on left ventricular assist device vs. intravenous inotropic therapy. J Heart Lung Transplant 2001;20:449-56.
173. John R, Lietz K, Burke E, et al. Intravenous immunoglobulin reduces anti- HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. Circulation 1999;100(19 Suppl):II229-35.
174. Johnson KE, Prieto M, Joyce LD, et al. Summary of the clinical use of the Symbion total artificial heart: a registry report. J Heart Lung Transplant 1992;11 (1 Pt 1):103-16.
175. Joyce D, Loebe M, Noon GP, et al. Revascularization and ventricular restoration in patients with ischemic heart failure: the STICH trial. Curr Opin Cardiol 2003;18:454-7.
176. Jurmann MJ, Weng Y, Drews T, et al. Permanent mechanical circulatory support in patients of advanced age. Eur J Cardiothorac Surg 2004;25:610-8.
177. Kalya AV, Tector AJ, Crouch JD, et al. Comparison of Novacor and Heart Mate vented electric left ventricular assist devices in a single institution. J Heart Lung Transplant 2005;24:1973-5.
178. Kao W, McGee D, Liao Y, et al. Does heart transplantation confer additional benefit over medical therapy to patients who have waited >6 months for heart transplantation? J Am Coll Cardiol 1994;24:1547-51.
179. Katsumata T, Westaby S. Implantable axial flow impeller pumps. J Circ Support 1998;1:13-9.
180. Khan T, Delgado RM, Radovancevic B, et al. Dobutamine stress echocardiography predicts myocardial improvement in patients supported by left ventricular assist devices (LVADs): hemodynamic and histologic evidence of improvement before LVAD explantation. J Heart Lung Transplant 2003;22:137-46.
181. Kihara S, Kawai A, Fukuda T, et al. Effects of milrinone for right ventricular failure after left ventricular assist device implantation. Heart Vessels 2002;16:69-71.
182. Kirklin JK. The importance of the Mechanical Circulatory Support Database. A plea for commitment. J Heart Lung Transplant 2001;20:803-4.
183. Kirklin JK. Developmental history of mechanical circulatory support. In: Frazier OH, Kirklin JK (eds.). Mechanical Circulatory Support (ISHLT Monograph Series, Vol. 1). Elsevier, Philadelphia, 2006, pp. 1-8.
184. Kirklin JK, Holman WL. Mechanical circulatory support therapy as a bridge to transplant or recovery (new advances). Curr Opin Cardiol 2006;21:120-6.
185. Kirklin JW, Barratt-Boyes BG. Cardiac Surgery (2nd ed.). Churchill-Livingstone, New York, 1992.
186. Klotz S, Deng MC, Stypmann J, et al. Left ventricular pressure and volume unloading during pulsatile versus nonpulsatile left ventricular assist device support. Ann Thorac Surg 2004;77:143-9; discussion 149-50.
187. Klotz S, Stypmann J, Welp H, et al. Does continuous flow left ventricular assist device technology have a positive impact on outcome pretransplant and posttransplant? Ann Thorac Surg 2006;82:1774-8.
188. Kocher AA, Schuster MD, Szabolcs MJ, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001;7:430-6.
189. Koelling TM, Joseph S, Aaronson KD. Heart failure survival score continues to predict clinical outcomes in patients with heart failure receiving beta-blockers. J Heart Lung Transplant 2004;23:1414-22.
190. Koster A, Loebe M, Hansen R, et al. Alterations in coagulation after implantation of a pulsatile Novacor LVAD and the axial flow Micro Med DeBakey LVAD. Ann Thorac Surg 2000;70:533-7.
191. Kress JP, Pohlman AS, O'Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 2000;342:1471-7.
192. Kron IL, Flanagan TL, Blackbourne LH, et al. Coronary revascularization rather than cardiac transplantation for chronic ischemic cardiomyopathy. Ann Surg 1989;210:348-54.
193. Kucuker SA, Stetson SJ, Becker KA, et al. Evidence of improved right ventricular structure after LVAD support in patients with end-stage cardiomyopathy. J Heart Lung Transplant 2004;23(1):28-35.
194. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001;345:588-95.
195. Lansman SL, Cohen M, Galla JD, et al. Coronary bypass with ejection fraction of 0.20 or less using centigrade cardioplegia: long-term follow-up. Ann Thorac Surg 1993;56:480-6.
196. Lazar RM, Shapiro PA, Jaski BE, et al. Neurological events during long-term mechanical circulatory support for heart failure: the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) experience. Circulation 2004;109:2423-7.
197. Leor J, Aboulafia-Etzion S, Dar A, et al. Bioengineered cardiac grafts: a new approach to repair the infarcted myocardium? Circulation 2000;102(19 Suppl 3):III56-61.
198. Leprince P, Combes A, Bonnet N, et al. Circulatory support for fulminant myocarditis: consideration for implantation, weaning and explantation. Eur J Cardiothorac Surg 2003;24:399-403.
199. Levine TB, Levine AB, Goldberg AD, et al. Clinical status of patients removed from a transplant waiting list rivals that of transplant recipients at significant cost savings. Am Heart J 1996;132:1189-94.
200. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002;347:1397-402.
201. Liang H, Lin H, Weng Y, et al. Prediction of cardiac function after weaning from ventricular assist devices. J Thorac Cardiovasc Surg 2005;130:1555-60.
202. Liaw PC, Esmon CT, Kahnamoui K, et al. Patients with severe sepsis vary markedly in their ability to generate activated protein C. Blood 2004; 104:3958-64.
203. Lietz K, Miller LW. Will left-ventricular assist device therapy replace heart transplantation in the foreseeable future? Curr Opin Cardiol 2005;20:132-7.
204. Lowes BD, Shakar SF, Metra M, et al. Rationale and design of the enoximone clinical trials program. J Card Fail 2005;11:659-69.
205. Lucas C, Johnson W, Hamilton MA, et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J 2000;140:824-6.
206. Luckraz H, Woods M, Large SR; Papworth VAD Group. And hemolysis goes on: ventricular assist device in combination with veno-venous hemofiltration. Ann Thorac Surg 2002;73:546-8.
207. MacDonald PS, Keogh A, Mundy J. Adjunctive use of inhaled nitric oxide during implantation of left ventricular assist device. J Heart Lung Transplant 1998;17:312-6.
208. Malay MB, Ashton JL, Dahl K, et al. Heterogeneity of the vasoconstrictor effect of vasopressin in septic shock. Crit Care Med 2004;32:1327-31.
209. Mancini D, Goldsmith R, Levin H, et al. Comparison of exercise performance in patients with chronic severe heart failure versus left ventricular assist devices. Circulation 1998a;98:1178-83.
210. Mancini DM, Beniaminovitz A, Levin H, et al. Low incidence of myocardial recovery after left ventricular assist device implantation in patients with chronic heart failure. Circulation 1998b;98:2383-9.
211. Mancini DM, Eisen H, Kussmaul W, et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991;83:778-86.
212. Mangano DT, Tudor IC, Dietzel C; Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006;354:353-65.
213. Mangi AA, Christison-Lagay ER, Torchiana DF, et al. Gastrointestinal complications in patients undergoing heart operation: an analysis of 8709 consecutive cardiac surgical patients. Ann Surg 2005;241:895-901.
214. Marzo KP, Wilson JR, Mancini DM. Effects of cardiac transplantation on ventilatory response to exercise. Am J Cardiol 1992;69:547-553.
215. Masai T, Sawa Y, Ohtake S, et al. Hepatic dysfunction after left ventricular mechanical assist in patients with end-stage heart failure: role of inflammatory response and hepatic microcirculation. Ann Thorac Surg 2002;73:549-55.
216. Massad MG, Cook DJ, Schmitt SK, et al. Factors influencing HLA sensitization in implantable LVAD recipients. Ann Thorac Surg 1997;64:1120-5.
217. May-Newman KD, Hillen BK, Sironda CS, DembitskyW. Effect of LVAD outflow conduit insertion angle on flow through the native aorta. J Med Eng Technol 2004;28:105-9.
218. McBride LR, Naunheim KS, Fiore AC, et al. Risk analysis in patients bridged to transplantation. Ann Thorac Surg 2001;71:1839-44.
219. McCarthy PM, Starling RC, Young JB, et al. Left ventricular reduction surgery with mitral valve repair. J Heart Lung Transplant 2000;19:S64-7.
220. McMurray JJ, Pfeffer MA. Heart failure. Lancet 2005;365:1877-89.
221. McMurray JJ, Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart 2000;83:596-602.
222. Mehra MR, Kobashigawa J, Starling R, et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates - 2006. J Heart Lung Transplant 2006;25:1024-42.
223. MERIT Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
224. Mickleborough LL, Maruyama H, Takagi Y, et al. Results of revascularization in patients with severe left ventricular dysfunction. Circulation 1995;92(Suppl II):S73-9.
225. Miller LW. Patient selection for the use of ventricular assist devices as a bridge to transplantation. Ann Thorac Surg 2003;75(6 Suppl):S66-71.
226. Miller LW, Lietz K. Candidate selection for long-term left ventricular assist device therapy for refractory heart failure. J Heart Lung Transplant 2006;25:756-64.
227. Miller LW, Nelson KE, Bostic RR, et al. Hospital costs for left ventricular assist devices for destination therapy: lower costs for implantation in the post- REMATCH era. J Heart Lung Transplant 2006;25:778-84.
228. Minami K, El-Banayosy A, Sezai A, et al. Morbidity and outcome after mechanical ventricular support using Thoratec, Novacor, and Heart Mate for bridging to heart transplantation. Artif Organs 2000;24:421-6.
229. Moazami N, Itescu S, Williams MR, et al. Platelet transfusions are associated with the development of anti-major histocompatibility complex class I antibodies in patients with left ventricular assist support. J Heart Lung Transplant 1998;17:876-80.
230. Moose C. The Grateful Heart - Diary of a Heart Transplant. Rosalie Ink Publications, New York, 2005.
231. Morales DL, Gregg D, Helman DN, et al. Arginine vasopressin in the treatment of 50 patients with postcardiotomy vasodilatory shock. Ann Thorac Surg 2000;69:102-6.
232. Morgan JA, John R, Lee BJ, et al. Is severe right ventricular failure in left ventricular assist device recipients a risk factor for unsuccessful bridging to transplant and post-transplant mortality. Ann Thorac Surg 2004;77:859-63.
233. Morgan JA, Park Y, Oz MC, Naka Y. Device related infections while on left ventricular assist device support do not adversely impact bridging to transplant or posttransplant survival. ASAIO J 2003;49:748-50.
234. Morris RJ, Pochettino A, O'Hara M, et al. Emergent mechanical support in the community: improvement with early transplant center referral. J Heart Lung Transplant 2005;24:764-8.
235. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996;335:1933-40.
236. Moss AJ, Zareba W, Hall WJ, et al.; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83.
237. Müller J, Wallukat G, Weng YG, et al. Weaning from mechanical cardiac support in patients with idiopathic dilated cardiomyopathy. Circulation 1997; 96:542-9.
238. Mustafa I, Leverve X. Metabolic and nutritional disorders in cardiac cachexia. Nutrition 2001;17:756-60.
239. Myers TJ, Khan T, Frazier OH. Infectious complications associated with ventricular assist systems. ASAIO J 2000;46:S28-36.
240. Nabavi DG, Georgiadis D, Mumme T, et al. Clinical relevance of intracranial microembolic signals in patients with left ventricular assist devices. A prospective study. Stroke 1996;27:891-6.
241. Nguyen MT, Ross GF, Dent CL, Devarajan P. Early prediction of acute renal injury using urinary proteomics. Am J Nephrol 2005;25:318-26.
242. Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:384-416.
243. Novis BK, Roizen MF, Aronson S, Thisted RA. Association of preoperative risk factors with postoperative acute renal failure. Anesth Analg 1994;78:143-9.
244. Nurozler F, Argenziano M, Oz MC, Naka Y. Fungal left ventricular assist device endocarditis. Ann Thorac Surg 2001;71:614-8.
245. O'Brien BJ, Buxton MJ, Ferguson BA. Measuring the effectiveness of heart transplant programmes: quality of life data and their relationship to survival analysis. J Chronic Dis 1987;40(Suppl):137S-58S.
246. O'Neill AJ, Doyle BT, Molloy E, et al. Gene expression profile of inflammatory neutrophils: alterations in the inhibitors of apoptosis proteins during spontaneous and delayed apoptosis. Shock 2004;21:51-8.
247. Ochiai Y, McCarthy PM, Smedira NG, et al. Predictors of severe right ventricular failure after implantable left ventricular assist device insertion: analysis of 245 patients. Circulation 2002;106(12 Suppl 1):I198-202.
248. Olman MA, White KE, Ware LB, et al. Pulmonary edema fluid from patients with early lung injury stimulates fibroblast proliferation through IL-1 beta-induced IL-6 expression. J Immunol 2004;172:2668-77.
249. Olson PS, Kassis E, Niebuhr-Jorgensen U. Coronary artery bypass surgery in patients with severe left ventricular dysfunction. Thorac Cardiovasc Surg 1993;41:118-20.
250. Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001;410:701-5.
251. Ostermann ME, Chang RW; Riyadh ICU Program Users Group. Prognosis of acute renal failure: an evaluation of proposed consensus criteria. Intensive Care Med 2005;31:250-6.
252. Oz MC, Gelijns AC, Miller L, et al. Left ventricular assist devices as permanent heart failure therapy: the price of progress. Ann Surg 2003;238:577-83.
253. Oz MC, Goldstein DJ, Pepino P, et al. Screening scale predicts patients successfully receiving long-term implantable left ventricular assist devices. Circulation 1995;92(9 Suppl):II169-73.
254. Oz MC, Rose EA, Slater J, et al. Malignant ventricular arrhythmias are well tolerated in patients receiving long-term left ventricular assist devices. J Am Coll Cardiol 1994;24:1688-91.
255. Pachot A, Monneret G, Brion A, et al. Messenger RNA expression of major histocompatibility complex class II genes in whole blood from septic shock patients. Int Care Med 2005;33:31-8.
256. Packer M, Abraham W, for the MIRACLE Trial. Effect of cardiac resynchronization on a composite clinical status endpoint in patients with chronic heart failure: results of the MIRACLE trial (abstr). J Card Fail 2001;17(Suppl 2):53.
257. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991;325:1468-75.
258. Packer M, Coats AJ, Fowler MB, et al.; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8.
259. Pae WE, Pierce WS. Combined registry for the clinical use of mechanical ventricular assist pumps and the total artificial heart. J Heart Transplant 1986;5:6-7.
260. Pae WE Jr, Kormos RL, Greene PS, Sapirstein W. Database: relevant or not. Ann Thorac Surg 2001;71:S204-9.
261. Park MH, Goudreau E, Tolman DE, et al. Fluoroscopy and selective angiography of left ventricular assist system inflow cannula as a method of detecting cannula entrapment. Cathet Cardiovasc Diagn 1998;44:47-51.
262. Park SJ, Liao KK, Segurola R, et al. Management of aortic insufficiency in patients with left ventricular assist devices: a simple coaptation stitch method (Park's stitch). J Thorac Cardiovasc Surg 2004;127:264-6.
263. Park SJ, Tector A, Piccioni W, et al. Left ventricular assist devices as destination therapy: a new look at survival. J Thorac Cardiovasc Surg 2005;129:9-17.
264. Parker RA, Himmelfarb J, Tolkoff-Rubin N, et al. Prognosis of patients with acute renal failure requiring dialysis: results of a multicenter study. Am J Kidney Dis 1998;32:432-43.
265. Philbin EF. Comprehensive multidisciplinary programs for the management of patients with congestive heart failure. J Gen Intern Med 1999;14:130-5.
266. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.
267. Plenz G, Baba HA, Erren M, et al. Reversal of myocardial interleukin-6- mRNA expression following long-term left ventricular assist device support for myocarditis-associated low output syndrome (letter). J Heart Lung Transplant 1999;18:923-4.
268. Poirier V. Worldwide experience with the TCI Heart Mate system: issues and future perspective. Thorac Cardiovasc Surg 1999;47(Suppl 2):316-20.
269. Poole-Wilson PA, Swedberg K, Cleland JG, et al.; Carvedilol or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13.
270. Portner PM, Jansen PG, Oyer PE, et al. Improved outcomes with an implantable left ventricular assist system: a multicenter study. Ann Thorac Surg 2001; 71:205-9.
271. Portner PM, Oyer PE, Pennington DG, et al. Implantable electrical left ventricular assist system: bridge to transplantation and the future. Ann Thorac Surg 1989;47:142-50.
272. Poston RS, Husain S, Sorce D, et al. LVAD bloodstream infections: therapeutic rationale for transplantation after LVAD infection. J Heart Lung Transplant 2003;22:914-21.
273. Poston RS, Sorce DN, Husain S, et al. LVAD blood stream infection: therapeutic rationale for transplantation. J Heart Lung Transplant 2001;20:241-2.
274. Potapov EV, Jurmann MJ, Drews T, et al. Patients supported for over 4 years with left ventricular assist devices. Eur J Heart Fail 2006;8:756-9.
275. Prager KM, Oz M. Proposed policy for VAD removal. Ann Thorac Surg 2002;73:1688.
276. Prendergast TW, Todd BA, Beyer AJ 3rd, et al. Management of left ventricular assist device infection with heart transplantation. Ann Thorac Surg 1997;64:142-7.
277. Quaini E, Pavie A, Chieco S, Mambrito B. The Concerted Action 'Heart' European registry on clinical application of mechanical circulatory support systems: bridge to transplant. The Registry Scientific Committee. Eur J Cardiothorac Surg 1997;11:182-8.
278. Rao V, Oz MC, Edwards NM, Naka Y. A new off-pump technique for Thoratec right ventricular assist device insertion. Ann Thorac Surg 2001;71:1719-20.
279. Rao V, Oz MC, Flannery MA, et al. Revised screening scale to predict survival after insertion of a left ventricular assist device. J Thorac Cardiovasc Surg 2003;125:855-62.
280. Redfield MM. Heart failure - an epidemic of uncertain proportions. N Engl J Med 2002;347:1442-4.
281. Reinhartz O, Farrar DJ, Hershon JH, et al. Importance of preoperative liver function as a predictor of survival in patients supported with Thoratec ventricular assist devices as a bridge to transplantation. J Thorac Cardiovasc Surg 1998;116:633-40.
282. Reinlib L, Abraham W. Recovery from heart failure with circulatory assist: a working group of the National Heart, Lung, and Blood Institute. J Card Fail 2003;9:459-63.
283. Reiss N, El-Banayosy A, Arusoglu L, et al. Acute fulminant myocarditis in children and adolescents: the role of mechanical circulatory assist. ASAIO J 2006;52:211-4.
284. Rich MW, Beckham V, Wittenberg C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995;333:1190-5.
285. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 1996;93:841-2.
286. Richenbacher WE, Seemuth SC. Hospital discharge for the ventricular assist device patient: historical perspective and description of a successful program. ASAIO J 2001;47:590-5.
287. Rivers E, Nguyen B, Havstad S, et al.; Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-77.
288. Robbins RC, Oyer PE. Bridge to transplant with the Novacor left ventricular assist system. Ann Thorac Surg 1999;68:695-7.
289. Rodrigue-Way A, Burkhoff D, Geesaman BJ, et al. Sarcomeric genes involved in reverse remodeling of the heart during left ventricular assist device support. J Heart Lung Transplant 2005;24:73-80.
290. Rose EA, Gelijns AC, Moskowitz AJ, for the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001;345:1435-43.
291. Rose EA, Moskowitz AJ, Packer M, et al. The REMATCH trial: rationale, design, and end points. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure. Ann Thorac Surg 1999;67: 723-30.
292. Rose EA, Stevenson LW (eds.). Management of End-Stage Heart Disease. Lippincott-Raven Publishers, Philadelphia, 1998.
293. Rothenburger M, Wilhelm MJ, Hammel D, et al. Treatment of thrombus formation associated with the Micro Med DeBakey VAD using recombinant tissue plasminogen activator. Circulation 2002;106(12 Suppl 1):I189-92.
294. Ruf AE, Kremers WK, Chavez LL, et al. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 2005;11:336-43.
295. Russell JA. Management of sepsis. N Engl J Med 2006;355:1699-713.
296. Ryden L, for the Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet 1990;336:1-6.
297. Sabol VK. Nutrition assessment of the critically ill adult. AACN Clin Issues 2004;15:595-606.
298. Samuels LE, Holmes EC, Garwood P, Ferdinand F. Initial experience with the Abiomed AB5000 ventricular assist device system. Ann Thorac Surg 2005;80:309-12.
299. Samuels LE, Holmes EC, Petrucci R. Psychosocial and sexual concerns of patients with implantable left ventricular assist devices: a pilot study. J Thorac Cardiovasc Surg 2004;127:1432-5.
300. Samuels LE, Thomas MP, Holmes EC, et al. Insufficiency of the native aortic valve and left ventricular assist system inflow valve after support with an implantable left ventricular assist system: signs, symptoms, and concerns. J Thorac Cardiovasc Surg 2001;122:380-1.
301. Savage L. Quality of life among patients with a left ventricular assist device: what is new? AACN Clin Issues 2003;14:64-72.
302. Schmid C, Hammel D, Deng MC, et al. Ambulatory care of patients with left ventricular assist devices. Circulation 1999;100(Suppl II):II224-8.
303. Schmid C, Tjan TD, Etz C, et al. First clinical experience with the Incor left ventricular assist device. J Heart Lung Transplant 2005;24:1188-94.
304. Schmid C, Wilhelm M, Rothenburger M, et al. Effect of high dose platelet inhibitor treatment on thromboembolism in Novacor patients. Eur J Cardiothorac Surg 2000;17:331-5.
305. Schmidt LE, Dalhoff K. Alpha-fetoprotein is a predictor of outcome in acetaminophen-induced liver injury. Hepatology 2005;41:26-31.
306. Schonhofer B, Guo JJ, Suchi S, et al. The use of APACHE II prognostic system in difficult-to-wean patients after long-term mechanical ventilation. Eur J Anaesthesiol 2004;21:558-65.
307. Shah NB, Der E, Ruggerio C, et al. Prevention of hospitalizations for heart failure with an interactive home monitoring program. Am Heart J 1998;135: 373-8.
308. Shapiro PA, Levin HR, Oz MC. Left ventricular assist devices. Psychosocial burden and implications for heart transplant programs. Gen Hosp Psychiatry 1996;18(6 Suppl):30S-5S.
309. Sharma UC, Pokharel S, Evelo CT, Maessen JG. A systematic review of large scale and heterogeneous gene array data in heart failure. J Mol Cell Cardiol 2005;38:425-32.
310. Siegenthaler MP, Westaby S, Frazier OH, et al. Advanced heart failure: feasibility study of long-term continuous axial flow pump support. Eur Heart J 2005;26:1031-8.
311. Simon D, Fischer S, Grossman A, et al. Left ventricular assist device-related infection: treatment and outcome. Clin Infect Dis 2005a;40:1108-15.
312. Simon MA, Kormos RL, Murali S, et al. Myocardial recovery using ventricular assist devices: prevalence, clinical characteristics, and outcomes. Circulation 2005b;112(9 Suppl):I32-6.
313. Singh SN, Fletcher RD, Fisher SG, for the Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995;333: 77-88.
314. Sinha P, Chen JM, Flannery M, et al. Infections during left ventricular assist device support do not affect posttransplant outcomes. Circulation 2000;102 (19 Suppl 3):III194-9.
315. Sladen RN. Oliguria in the ICU. Systematic approach to diagnosis and treatment. Anesthesiol Clin North America 2000;18:739-52.
316. Slaughter MS, Silver MA, Farrar DJ, et al. A new method of monitoring recovery and weaning the Thoratec left ventricular assist device. Ann Thorac Surg 2001;71:215-8.
317. Slaughter MS, Sobieski MA, Koenig SC, et al. Left ventricular assist device weaning: hemodynamic response and relationship to stroke volume and rate reduction protocols. ASAIO J 2006;52:228-33.
318. Smart K, Jett GK. Late tamponade with mechanical circulatory support. Ann Thorac Surg 1998;66:2027-8.
319. Smits JMA, De Meester J, Deng MC, on behalf of the COCPIT Study Group and the Eurotransplant Heart Transplant Programs. Mortality rates after heart transplantation: how to compare center-specific outcome data? Transplantation 2003a;75:90-6.
320. Smits JMA, Deng MC, Hummel M, on behalf of the COCPIT Study Group. A prognostic model for predicting waiting list mortality for a total national cohort of adult heart transplant candidates. Transplantation 2003b;76:1185-9.
321. Song X, Throckmorton AL, Untaroiu A, et al. Axial flow blood pumps. ASAIO J 2003;49:355-364.
322. Spanier T, Oz M, Levin H, et al. Activation of coagulation and fibrinolytic pathways in patients with left ventricular assist devices. J Thorac Cardiovasc Surg 1996;112:1090-7.
323. Spanier TB, Chen JM, Oz MC, et al. Time-dependent cellular population of textured-surface left ventricular assist devices contributes to the development of a biphasic systemic procoagulant response. J Thorac Cardiovasc Surg 1999;118:404-13.
324. St. John Kolar D. Cardiovascular news: heart transplantation survival rate best in high-risk group. Circulation 2000;102:e-9024.
325. Stevenson LW. The evolving role of mechanical circulatory support in advanced heart failure. In: Frazier OH, Kirklin JK (eds.). Mechanical Circulatory Support (ISHLT Monograph Series, Vol. 1). Elsevier, Philadelphia, 2006.
326. Stevenson LW, Hamilton MA, Tillisch IH, et al.; Decreasing survival benefit from cardiac transplantation for outpatients as the waiting list lengthens. J Am Coll Cardiol 1991;18:919-25.
327. Stevenson LW, Kormos RL, Bourge RC, et al.; Mechanical cardiac support 2000: current applications and future trial design. J Am Coll Cardiol 2001;37: 340-70.
328. Stevenson LW, Miller LW, Desvigne-Nickens P, et al.; REMATCH Investigators. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure). Circulation 2004;110:975-81.
329. Stevenson LW, Shekar P. Ventricular assist devices for durable support. Circulation 2005;112:e111-5.
330. Stevenson LW, Steimle AE, Fonarow G, et al. Improvement in exercise capacity of candidates awaiting heart transplantation. J Am Coll Cardiol 1995;25:163-70.
331. Suman A, Barnes DS, Zein NN, et al. Predicting outcome after cardiac surgery in patients with cirrhosis: a comparison of Child-Pugh and MELD scores. Clin Gastroenterol Hepatol 2004;2:719-23.
332. Swartz MT, Lowdermilk GA, McBride LR. Refractory ventricular tachycardia as an indication for ventricular assist device support. J Thorac Cardiovasc Surg 1999;118:1119-20.
333. Swedberg K, for the CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987;316: 1429-35.
334. Swedberg K, Kjekshus J, Snapinn S. Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I. Eur Heart J 1999;20:136-9.
335. Sweeney MO, Ruskin JN, Garan H, et al. Influence of the implantable cardioverter/ defibrillator on sudden death and total mortality in patients evaluated for cardiac transplantation. Circulation 1995;92:3273-81.
336. Teerlink JR, Massie BM. The role of beta-blockers in preventing sudden death in heart failure. J Card Fail 2000;6(Suppl 1):25-33.
337. Texereau J, Pene F, Chiche JD, et al. Importance of hemostatic gene polymorphisms for susceptibility to and outcome of severe sepsis. Crit Care Med 2004;32(5 Suppl):Sl313-19.
338. Thakar CV, Arrigain S, et al. A clinical score to predict acute renal failure after cardiac surgery. J Am Soc Nephrol 2005;16:162-8.
339. Thalmann M, Schima H, Wieselthaler G, Wolner E. Physiology of continuous blood flow in recipients of rotary cardiac assist devices. J Heart Lung Transplant 2005;24:237-45.
340. Thoratec Corporation. Nutrition Management in Advanced Practice Guidelines for HeartMate® Destination Therapy. Report No. 1, 2004.
341. Tisol WB, Mueller DK, Hoy FB, et al. Ventricular assist device use with mechanical heart valves: an outcome series and literature review. Ann Thorac Surg 2001;72:2051-4.
342. Tjan TDT, Kondruweit M, Scheld HH, et al. The bad ventricle - revascularization versus transplantation. Thorac Cardiovasc Surg 2000;48:1-6.
343. Topkara VK, Dang NC, Barili F, et al. Predictors and outcomes of continuous veno-venous hemodialysis use after implantation of a left ventricular assist device. J Heart Lung Transplant 2006;25:404-8.
344. Topkara VK, Dang NC, Martens TP, et al. Bridging to transplantation with left ventricular assist devices: outcomes in patients aged 60 years and older. J Thorac Cardiovasc Surg 2005;130:881-2.
345. Toumpoulis IK, Anagnostopoulos CE, Swistel DG, DeRose JJ Jr. Does EuroSCORE predict length of stay and specific postoperative complications after cardiac surgery? Eur J Cardiothorac Surg 2005;27:128-33.
346. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345:1359-67.
347. Veenhuyzen GD, Singh SN, McAreavey D, et al. Prior coronary artery bypass surgery and risk of death among patients with ischemic left ventricular dysfunction. Circulation 2001;104:1489-93.
348. Vincent JL, Angus DC, Artigas A, et al.; Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 2003;31:834-40.
349. Vinsonneau C, Camus C, Combes A, et al.; Hemodiafe Study Group. Continuous venovenous haemodiafiltration versus intermittent haemodialysis for acute renal failure in patients with multiple-organ dysfunction syndrome: a multicentre randomised trial. Lancet 2006;368:379-85.
350. Wang JE. Can single nucleotide polymorphisms in innate immune receptors predict development of septic complications in intensive care unit patients? Crit Care Med 2005;33:695-6.
351. Wegner JA, DiNardo JA, Arabia FA, Copeland JG. Blood loss and transfusion requirements in patients implanted with a mechanical circulatory support device undergoing cardiac transplantation. J Heart Lung Transplant 2000;19:504-6.
352. Weissman C. Pulmonary complications after cardiac surgery. Semin Cardiothorac Vasc Anesth 2004;8:185-211.
353. Weitkemper HH, El-Banayosy A, Arusoglu L, et al. Mechanical circulatory support: reality and dreams - experience of a single center. J Extra Corpor Technol 2004;36:169-73.
354. Wieselthaler GM, Schima H, Hiesmayr M, et al. First clinical experience with the DeBakey VAD continuous-axial-flow pump for bridge to transplantation. Circulation 2000;101:256-9.
355. Wilhelm CR, Ristich J, Kormos RL, Wagner WR. Monocyte tissue factor expression and ongoing complement generation in ventricular assist device patients. Ann Thorac Surg 1998;65:1071-6.
356. Williams MR, Oz MC. Indications and patient selection for mechanical ventricular assistance. Ann Thorac Surg 2001;71(Suppl 3):S86-91.
357. Winkel E, Piccione W. Coronary artery bypass surgery in patients with left ventricular dysfunction: candidate selection and perioperative care. J Heart Lung Transplant 1997;16:S19-24.
358. Wright JC, Weinstein MC. Gains in life expectancy from medical interventions- standardizing data on outcomes. N Engl J Med 1998;339:380-6.
359. Wudel JH, Hlozek CC, Smedira NG, McCarthy PM. Extracorporeal life support as a post left ventricular assist device implant supplement. ASAIO J 1997;43:M441-3.
360. Yokomuro H, Li RK, Mickle DA, et al. Transplantation of cryopreserved cardiomyocytes. J Thorac Cardiovasc Surg 2001;121:98-107.
361. Yoo KJ, Li RK, Weisel RD, et al. Autologous smooth muscle cell transplantation improved heart function in dilated cardiomyopathy. Ann Thorac Surg 2000;70:859-65.
362. Young JB, Dunlap ME, Pfeffer MA, et al.; Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators and Committees. Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 2004;110:2618-26.
363. Young JB, Rogers JG, Portner PE et al. Bridge to eligibility: LVAS support in patients with relative contraindications to transplantation. J Heart Lung Transplant 2005;24:S75.
364. Zimpfer D, Wieselthaler G, Czerny M, et al. Neurocognitive function in patients with ventricular assist devices: a comparison of pulsatile and continuous blood flow devices. ASAIO J 2006;52:24-7.
365. Ziv O, Dizon J, Thosani A, et al. Effects of left ventricular assist device therapy on ventricular arrhythmias. J Am Coll Cardiol 2005;45:1428-34.